Vertex Pharma boosts immunotherapy business in $4.9 billion Alpine Immune deal

Vertex Pharmaceuticals will buy Alpine Immune Sciences for about $4.9 billion in cash, gaining access to the biotech firm's protein-based immunotherapies to treat autoimmune and inflammatory diseases, the companies said on Wednesday. The deal values each share of Alpine at $65, which represents a…#alpineimmunesciences #alpine #vertex
Source: Reuters: Health - Category: Consumer Health News Source Type: news